Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
about
Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purposeGlucocerebrosidase and Parkinson disease: Recent advancesGlucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies.The genetic background of Parkinson's disease: current progress and future prospects.Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.HDL and cholesterol handling in the brain.Endoplasmic reticulum and lysosomal Ca²⁺ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts.Promising Targets for the Treatment of Neurodegenerative Diseases.A Next Generation Multiscale View of Inborn Errors of Metabolism.Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment.New Directions in Gaucher Disease.Gaucher disease: Progress and ongoing challenges.The role of Ca2+ signaling in Parkinson's disease.The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease.Mutations in the glucocerebrosidase gene are responsible for Chinese patients with Parkinson's disease.Habitual behavior and dopamine cell vulnerability in Parkinson disease.A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons.Patients' Opinions on Genetic Counseling on the Increased Risk of Parkinson Disease among Gaucher Disease Carriers.Impaired gait kinematics in type 1 Gaucher's Disease.GBA-associated parkinsonism and dementia: beyond α-synucleinopathies?The contribution of mutant GBA to the development of Parkinson disease in Drosophila.Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis.
P2860
Q26785491-E338A462-616A-4C28-A7D8-0406BAA5BA0FQ27005669-3C68AB28-E6BA-4B3E-B5EA-6A512CB3A5F4Q30367337-FE72803E-1F7C-45DF-B16A-4BCDA1696C60Q31097119-AC3FC83D-22E9-4F44-BB2B-0D13A3D97A16Q34463167-31843BFD-4BAA-4EF3-9F69-8777B9A45AEAQ34513714-12FAE969-9B52-4666-8BAA-6BCA2CC4B166Q35971649-4AF105B3-796A-420F-8FBF-1461B1AE7E83Q37696004-0ECA5D11-EBD6-4044-BE43-A4BA2F48AE4FQ38218439-BE84B3A1-FFE1-448A-95ED-540503F92D12Q38389995-BE6BD0A8-2452-4B39-989F-6BE4429E4AAAQ38562084-79D5F5F7-96BC-4AE6-AA66-AB0C3361DCCAQ38681906-77658026-86F9-4F45-A87E-AD91C1CF7313Q38811401-6E0BC90B-D960-4C83-81C9-AEC53CC4BF4FQ38905996-7D7A8824-150A-4D3F-AFF0-0F9607CB3453Q39028972-D740EBD0-C6F3-47BE-B8F3-8087F3BE9378Q39281423-1668D55E-8ED6-4B61-9167-36CD2BAFA795Q39410832-730CBE2E-B126-4FD5-B4B5-F130A7ADD0E5Q41677841-A76AB510-592D-425B-95F3-E6D55341210CQ42177449-EE66D732-F53E-4BCA-96D6-6ADDB45C109FQ42315677-2BC4143D-E12F-4618-A957-67F49920CE43Q48181256-4ABB7A63-8BCC-4A67-A522-42CDBE8FD7ABQ48266068-DA5F01EA-134B-457F-B347-BD2375F3E59FQ48698312-E415CD21-45D6-454E-AA67-4696CFC98414Q52147014-C710466B-DF8F-4617-9288-1E525B28577CQ52848620-3E6AD5E8-528A-46BB-BCD3-4FF5EBAC9FBBQ55056377-B2DA4F29-787A-4F36-A642-CADC53299107
P2860
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
@en
type
label
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
@en
prefLabel
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
@en
P2860
P1433
P1476
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease.
@en
P2093
Michelle S Beavan
P2860
P304
P356
10.3109/07853890.2013.849003
P407
P577
2013-12-01T00:00:00Z